SCHEMBL4876786

SCHEMBL4876786

CC(C)c1ccc(S(=O)(=O)Nc2ccc(SC3CCN(C)CC3)cc2)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.56
MAPT P10636 2/20 0.56
LMNA P02545 1/20 0.56
PKM P14618 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
DRD2 P14416 5/20 0.52
DRD3 P35462 5/20 0.52
KCNH2 Q12809 5/20 0.52
HTR6 P50406 3/20 0.48
TRIM24 O15164 1/20 0.47
BRD1 O95696 1/20 0.47
BRPF1 P55201 1/20 0.47
HTR2A P28223 1/20 0.47
HTR2C P28335 1/20 0.47
POLB P06746 1/20 0.46
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
PGR P06401 1/20 0.43
SLC2A1 P11166 1/20 0.43
ALOX12 P18054 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4876689 0.88 CES1 (0.54) ALDH1A1MAPTPKMDRD2DRD3
SCHEMBL4874458 0.87 ALDH1A1 (0.44) ALDH1A1MAPTLMNASMN1; SMN2DRD2
SCHEMBL4866321 0.87 ALDH1A1 (0.57) ALDH1A1MAPTLMNASMN1; SMN2POLB
SCHEMBL4876385 0.86 HTR6 (0.49) ALDH1A1MAPTLMNASMN1; SMN2DRD2
SCHEMBL4873695 0.86 ALDH1A1 (0.58) ALDH1A1MAPTPKMSMN1; SMN2HTR2A
SCHEMBL6617076 0.84 ALDH1A1 (0.60) ALDH1A1MAPTLMNAPKMSMN1; SMN2
SCHEMBL4874044 0.84 ALDH1A1 (0.62) ALDH1A1MAPTLMNASMN1; SMN2DRD2
SCHEMBL4876622 0.83 ALDH1A1 (0.60) ALDH1A1PKMPOLBMEN1KMT2A
SCHEMBL4868720 0.83 MAPT (0.49) ALDH1A1MAPTLMNAPKMSMN1; SMN2
SCHEMBL4866404 0.82 HTR6 (0.55) ALDH1A1MAPTLMNAPKMSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7408067-B2 Aza-cyclic compounds as modulators of acetylcholine receptors MERCK + CO., INC. (US) 2008-08-05 US disclosed
US-20050070520-A1 Aza-cyclic compounds as modulators of acetylcholine receptors MERCK SHARP & DOHME CORP. 2005-03-31 US disclosed
EP-1467986-A1 AZA-CYCLIC COMPOUNDS AS MODULATORS OF ACETYLCHOLINE RECEPTORS ELI LILLY AND COMPANY (US) 2004-10-20 EP disclosed
WO-2003062224-A1 AZA-CYCLIC COMPOUNDS AS MODULATORS OF ACETYLCHOLINE RECEPTORS ELI LILLY AND COMPANY (US) 2003-07-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050070520-A1 Aza-cyclic compounds as modulators of acetylcholine receptors CHRNG, CHRNA4, CHRNB4 ALDH1A1 1088/4885MAPT 3850/4885LMNA 4805/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.